Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2018 | 03-2017 | 03-2016 | 03-2015 | 03-2014 | |
| Sales | 8,510 | 9,054 | 4,437 | 0 | 0 |
| Cost of Goods | 5,135 | 5,121 | 2,381 | N/A | N/A |
| Gross Profit | 3,375 | 3,934 | 2,056 | N/A | N/A |
| Operating Expenses | 10,039 | 9,143 | 5,232 | 4,421 | 2,671 |
| Operating Income | -6,664 | -5,209 | -3,176 | -4,421 | -2,671 |
| Interest Expense | 1,178 | 835 | 325 | 0 | 15 |
| Other Income | 137 | -67 | 5 | 20 | 6 |
| Pre-tax Income | -7,705 | -6,111 | -3,496 | -4,401 | -2,680 |
| Income Tax | -275 | -365 | -865 | N/A | N/A |
| Net Income Continuous | -7,430 | -5,746 | -2,631 | -4,401 | -2,680 |
| Net Income | $-7,430 | $-5,746 | $-2,631 | $-4,401 | $-2,680 |
| EPS Basic Total Ops | -0.50 | -0.60 | -0.40 | -1.20 | -1.00 |
| EPS Basic Continuous Ops | -0.50 | -0.60 | -0.40 | -1.20 | -1.00 |
| EPS Diluted Total Ops | -0.50 | -0.60 | -0.40 | -1.20 | -1.00 |
| EPS Diluted Continuous Ops | -0.50 | -0.60 | -0.40 | -1.20 | -1.00 |
| EBITDA(a) | $-6,150 | $-4,923 | $-3,010 | $-4,401 | $-2,665 |